J Periodontal Implant Sci.  2014 Jun;44(3):118-125. 10.5051/jpis.2014.44.3.118.

Effects of scaling and root planing with or without a local drug delivery system on the gingival crevicular fluid leptin level in chronic periodontitis patients: a clinico-biochemical study

• Meharwade
• Gayathri G
• Mehta DS

• KMID: 2012986
• DOI: http://doi.org/10.5051/jpis.2014.44.3.118

Abstract

PURPOSE
The present split mouth study evaluates the effect of nonsurgical periodontal treatment on the gingival crevicular fluid (GCF) leptin level in chronic periodontitis.
METHODS
Ninety sites from 30 nonobese chronic periodontitis patients were selected and divided as follows: group I, 30 healthy sites receiving no treatment; group II, 30 periodontitis sites receiving scaling and root planing (SRP); and group III, 30 periodontitis sites receiving SRP with tetracycline local drug delivery. At baseline, after GCF sampling and clinical parameter recording, the assigned treatment was performed for the study groups. During recall visits, GCF sampling followed by clinical parameter recording was done for groups II and III.
RESULTS
Reductions in the probing depth and the clinical attachment level (CAL) were highly significant at different time intervals (except between day 0 and 45) in both groups II and III. Upon comparison, group III showed significant gain in CAL between day 0 and 15 and between day 0 and 45. After treatment, the reduction in the GCF leptin level was more significant in group III than in group II at day 15 but re-elevated almost to the pretreatment levels at day 45.
CONCLUSIONS
Nonsurgical periodontal therapies were not effective in maintaining stable reduction in the GCF leptin level during the study period.

Keyword

Chronic periodontitis; Drug delivery system; Gingival crevicular fluid; Leptin; Randomized controlled trial

MeSH Terms

Chronic Periodontitis*
Drug Delivery Systems*
Gingival Crevicular Fluid*
Humans
Leptin*
Mouth
Periodontitis
Root Planing*
Tetracycline
Leptin
Tetracycline

Figure

• 

  Figure 1 Collection of gingival crevicular fluid sample by using a microcapillary pipette.

• 

  Figure 2 Measurement of the clinical attachment level by using a customized acrylic stent.

• 

  Figure 3 Local drug delivery for group III site. Group III: sites treated with scaling and root planning and local drug delivery.

• 

  Figure 4 Gingival crevicular fluid leptin levels at different time intervals. SRP: scaling and root planning sites, LDD: local drug delivery sites.

Reference

1. Hugoson A, Sjodin B, Norderyd O. Trends over 30 years, 1973-2003, in the prevalence and severity of periodontal disease. J Clin Periodontol. 2008; 35:405–414.

2. Genco RJ. Host responses in periodontal diseases: current concepts. J Periodontol. 1992; 63:4 Suppl. 338–355.

3. Mombelli A, Lehmann B, Tonetti M, Lang NP. Clinical response to local delivery of tetracycline in relation to overall and local periodontal conditions. J Clin Periodontol. 1997; 24:470–477.

4. Uitto VJ. Gingival crevice fluid: an introduction. Periodontol 2000. 2003; 31:9–11.

5. Johnson RB, Serio FG. Leptin within healthy and diseased human gingiva. J Periodontol. 2001; 72:1254–1257.

6. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372:425–432.

7. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol. 2005; 174:3137–3142.

8. Range H, Poitou C, Boillot A, Ciangura C, Katsahian S, Lacorte JM, et al. Orosomucoid, a new biomarker in the association between obesity and periodontitis. PLoS One. 2013; 8:e57645.

9. Karthikeyan BV, Pradeep AR. Leptin levels in gingival crevicular fluid in periodontal health and disease. J Periodontal Res. 2007; 42:300–304.

10. Karthikeyan BV, Pradeep AR. Gingival crevicular fluid and serum leptin: their relationship to periodontal health and disease. J Clin Periodontol. 2007; 34:467–472.

11. Shimada Y, Komatsu Y, Ikezawa-Suzuki I, Tai H, Sugita N, Yoshie H. The effect of periodontal treatment on serum leptin, interleukin-6, and C-reactive protein. J Periodontol. 2010; 81:1118–1123.

12. Walker CB, Pappas JD, Tyler KZ, Cohen S, Gordon JM. Antibiotic susceptibilities of periodontal bacteria. In vitro susceptibilities to eight antimicrobial agents. J Periodontol. 1985; 56:11 Suppl. 67–74.

13. Goodson JM, Offenbacher S, Farr DH, Hogan PE. Periodontal disease treatment by local drug delivery. J Periodontol. 1985; 56:265–272.

14. Bjorvatn K, Skaug N, Selvig KA. Tetracycline-impregnated enamel and dentin: duration of antimicrobial capacity. Scand J Dent Res. 1985; 93:192–197.

15. Morrison SL, Cobb CM, Kazakos GM, Killoy WJ. Root surface characteristics associated with subgingival placement of monolithic tetracycline-impregnated fibers. J Periodontol. 1992; 63:137–143.

16. Lesaffre E, Garcia Zattera MJ, Redmond C, Huber H, Needleman I. ISCB Subcommittee on Dentistry. Reported methodological quality of split-mouth studies. J Clin Periodontol. 2007; 34:756–761.

17. Silness J, Loe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condtion. Acta Odontol Scand. 1964; 22:121–135.

18. Loe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand. 1963; 21:533–551.

19. Muhlemann HR, Son S. Gingival sulcus bleeding: a leading symptom in initial gingivitis. Helv Odontol Acta. 1971; 15:107–113.

20. Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000; 62:413–437.

21. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol. 2000; 143:293–311.

22. Chaffee BW, Weston SJ. Association between chronic periodontal disease and obesity: a systematic review and meta-analysis. J Periodontol. 2010; 81:1708–1724.

23. Suvan J, D'Aiuto F, Moles DR, Petrie A, Donos N. Association between overweight/obesity and periodontitis in adults: a systematic review. Obes Rev. 2011; 12:e381–e404.

24. Bozkurt FY, Yetkin Ay Z, Sutcu R, Delibas N, Demirel R. Gingival crevicular fluid leptin levels in periodontitis patients with long-term and heavy smoking. J Periodontol. 2006; 77:634–640.

25. Saito T, Yamaguchi N, Shimazaki Y, Hayashida H, Yonemoto K, Doi Y, et al. Serum levels of resistin and adiponectin in women with periodontitis: the Hisayama study. J Dent Res. 2008; 87:319–322.

26. Slots J, Rams TE. Antibiotics in periodontal therapy: advantages and disadvantages. J Clin Periodontol. 1990; 17(7 Pt 2):479–493.

27. Rams TE, Keyes PH. A rationale for the management of periodontal diseases: effects of tetracycline on subgingival bacteria. J Am Dent Assoc. 1983; 107:37–41.

28. Baker PJ, Evans RT, Coburn RA, Genco RJ. Tetracycline and its derivatives strongly bind to and are released from the tooth surface in active form. J Periodontol. 1983; 54:580–585.

29. Garrett S, Johnson L, Drisko CH, Adams DF, Bandt C, Beiswanger B, et al. Two multi-center studies evaluating locally delivered doxycycline hyclate, placebo control, oral hygiene, and scaling and root planing in the treatment of periodontitis. J Periodontol. 1999; 70:490–503.

30. Polson AM, Garrett S, Stoller NH, Bandt CL, Hanes PJ, Killoy WJ, et al. Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. J Periodontol. 1997; 68:119–126.

31. Drisko CL, Cobb CM, Killoy WJ, Michalowicz BS, Pihlstrom BL, Lowenguth RA, et al. Evaluation of periodontal treatments using controlled-release tetracycline fibers: clinical response. J Periodontol. 1995; 66:692–699.

32. Friesen LR, Williams KB, Krause LS, Killoy WJ. Controlled local delivery of tetracycline with polymer strips in the treatment of periodontitis. J Periodontol. 2002; 73:13–19.

33. Heijl L, Dahlen G, Sundin Y, Wenander A, Goodson JM. A 4-quadrant comparative study of periodontal treatment using tetracycline-containing drug delivery fibers and scaling. J Clin Periodontol. 1991; 18:111–116.

34. Eckles TA, Reinhardt RA, Dyer JK, Tussing GJ, Szydlowski WM, DuBous LM. Intracrevicular application of tetracycline in white petrolatum for the treatment of periodontal disease. J Clin Periodontol. 1990; 17(7 Pt 1):454–462.

35. Goodson JM, Holborow D, Dunn RL, Hogan P, Dunham S. Monolithic tetracycline-containing fibers for controlled delivery to periodontal pockets. J Periodontol. 1983; 54:575–579.

36. Tonetti MS, Pini-Prato G, Cortellini P. Principles and clinical applications of periodontal controlled drug delivery with tetracycline fibers. Int J Periodontics Restorative Dent. 1994; 14:421–435.

37. Sorensen T, Echwald S, Holm JC. Leptin in obesity. BMJ. 1996; 313:953–954.

38. Ge H, Huang L, Pourbahrami T, Li C. Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo. J Biol Chem. 2002; 277:45898–45903.

39. Włodarski K, Włodarski P. Leptin as a modulator of osteogenesis. Ortop Traumatol Rehabil. 2009; 11:1–6.

40. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000; 100:197–207.